<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04227938</url>
  </required_header>
  <id_info>
    <org_study_id>AIS-A02</org_study_id>
    <nct_id>NCT04227938</nct_id>
  </id_info>
  <brief_title>Study of ALPN-101 in Steroid-resistant or Steroid-refractory Acute GVHD Versus Host Disease</brief_title>
  <acronym>Balance</acronym>
  <official_title>An Open-label Study of ALPN-101 in Steroid-resistant or Steroid-refractory Acute Graft Versus Host Disease (aGVHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alpine Immune Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alpine Immune Sciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Balance study will assess the safety, tolerability, and efficacy of an investigational&#xD;
      drug called ALPN-101 in adults with steroid-resistant or steroid-refractory acute graft&#xD;
      versus host disease (aGVHD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AIS-A02 is a Phase 1b open-label study of ALPN-101 administered to adult subjects with&#xD;
      steroid-resistant or steroid-refractory acute graft versus host disease (aGVHD).&#xD;
&#xD;
      It will be conducted at approximately 10 US sites. Up to 72 subjects will be enrolled in Part&#xD;
      A (dose escalation) and up to 25 subjects will be enrolled in Part B (dose expansion).&#xD;
&#xD;
      In each Part, safety and efficacy assessments will be performed throughout the dosing and&#xD;
      follow-up periods, and multiple PK and PD samples will be collected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Change in sponsor strategy&#xD;
  </why_stopped>
  <start_date type="Actual">May 11, 2020</start_date>
  <completion_date type="Actual">May 21, 2020</completion_date>
  <primary_completion_date type="Actual">May 21, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>A single dose of ALPN-101 will be administered via intravenous (IV) infusion. Multiple, ascending dose levels will be evaluated in cohorts of 3-6 subjects in Part A. In Part B, a single dose level-as identified in Part A-is planned.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>From study Day 1 (dosing of ALPN-101) until Day 29</time_frame>
    <description>The incidence, severity, and seriousness of AEs, including dose-limiting toxicities, assessed by CTCAE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>From study Day 1 (dosing of ALPN-101) until the date of best response, assessed up to 36 months</time_frame>
    <description>Assessed by MAGIC criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>From the date of best response until disease progression, assessed up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure-free survival (FFS)</measure>
    <time_frame>From study Day 1 (dosing of ALPN-101) until relapse, initiation of new systemic therapy, or non-relapse mortality; assessed up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>From study Day 1 (dosing of ALPN-101) until disease (aGVHD)-related event or death due to any cause, assessed up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality (NRM)</measure>
    <time_frame>From study Day 1 (dosing of ALPN-101) until progression or death due to any cause without prior progression, assessed up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Malignancy relapse/progression (MR)</measure>
    <time_frame>From study Day 1 (dosing of ALPN-101) until the date of relapse/progression of the primary malignancy, assessed up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From study Day 1 (dosing of ALPN-101) until death due to any cause, assessed up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum observed concentration (tmax) of ALPN-101</measure>
    <time_frame>From study Day 1 (dosing of ALPN-101) until Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax) of ALPN-101</measure>
    <time_frame>From study Day 1 (dosing of ALPN-101) until Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC) of ALPN-101</measure>
    <time_frame>From study Day 1 (dosing of ALPN-101) until Day 29</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Graft Vs Host Disease</condition>
  <arm_group>
    <arm_group_label>ALPN-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive a single dose of ALPN-101. In Part A, ascending dose levels of ALPN-101 will be evaluated. In Part B, a single dose level of ALPN-101-as identified in Part A-will be evaluated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALPN-101</intervention_name>
    <description>A single dose of ALPN-101 will be administered via intravenous infusion.</description>
    <arm_group_label>ALPN-101</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years&#xD;
&#xD;
          2. Status post first allogeneic stem cell transplantation (allo-SCT) from any donor&#xD;
             source using any conditioning regimen.&#xD;
&#xD;
          3. Grade Ⅱ-Ⅳ acute GVHD per Mount Sinai Acute GVHD international Consortium (MAGIC)&#xD;
             criteria.&#xD;
&#xD;
          4. Corticosteroid resistant or refractory as defined as any of the following:&#xD;
&#xD;
               1. Progression of aGVHD within 5 days following initiation of treatment with ≥ 2&#xD;
                  mg/kg/day of prednisone or equivalent;&#xD;
&#xD;
               2. Failure to improve within 7 days following initiation of treatment with ≥ 2&#xD;
                  mg/kg/day of prednisone or equivalent; or&#xD;
&#xD;
               3. Incomplete response (failure to achieve Complete Response) after 28 days of&#xD;
                  immunosuppressive treatment including steroids (treatment with ≥ 2 mg/kg/day of&#xD;
                  prednisone or equivalent).&#xD;
&#xD;
          5. Must agree to use appropriate contraception.&#xD;
&#xD;
          6. Female subjects must not be pregnant or breastfeeding.&#xD;
&#xD;
             In addition, the following criteria must be met prior to dosing with ALPN-101 on Day&#xD;
             1:&#xD;
&#xD;
          7. Karnofsky performance score ≥ 40.&#xD;
&#xD;
          8. No evidence of an active, uncontrolled bacterial, viral, or fungal infection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current veno-occlusive disease, or current treatment with dialysis or mechanical&#xD;
             ventilation associated with GVHD.&#xD;
&#xD;
          2. Prior donor lymphocyte infusion (DLI).&#xD;
&#xD;
          3. Receipt of any live vaccine within 4 weeks of ALPN-101 dosing.&#xD;
&#xD;
          4. Presence of any active malignant disease.&#xD;
&#xD;
          5. Corticosteroid therapy at doses &gt; 1 mg/kg/day prednisone or equivalent for indications&#xD;
             other than GVHD ≤ 7 days p ALPN-101 dosing.&#xD;
&#xD;
          6. Treatment with any of the following ≤ 2 weeks prior to ALPN-101 dosing: targeted&#xD;
             inhibitors of the CD28/CD80/86 pathway (e.g. abatacept, belatacept), targeted&#xD;
             inhibitors of the ICOS/ICOSL pathway&#xD;
&#xD;
          7. Initiation of treatment with salvage therapy &lt; 2 days prior to ALPN-101 dosing.&#xD;
             Concurrent salvage therapy that is intended to be continued must be at a stable dose&#xD;
             for ≥ 2 days prior to ALPN-101 dosing.&#xD;
&#xD;
          8. Treatment for aGVHD with adoptive cell therapy, investigational agents, devices, or&#xD;
             procedures ≤ 2 weeks or 5 half-lives-whichever is greater-prior to ALPN-101 dosing,&#xD;
             unless approved by the medical monitor and sponsor; prior treatment with mesenchymal&#xD;
             stem cells is permitted.&#xD;
&#xD;
          9. Known allergies, hypersensitivity, or intolerance to study drug, excipients, or&#xD;
             similar compounds.&#xD;
&#xD;
         10. Any medical complications or conditions that would, in the investigator's judgment,&#xD;
             interfere with full participation in the study, including administration of study drug&#xD;
             and attending required study visits; pose a significant risk to the participant; or&#xD;
             interfere with interpretation of study data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Hillson, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alpine Immune Sciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Center for Blood Cancer</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. David's South Austin medical Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>January 6, 2020</study_first_submitted>
  <study_first_submitted_qc>January 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2020</study_first_posted>
  <last_update_submitted>August 24, 2020</last_update_submitted>
  <last_update_submitted_qc>August 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>steroid-resistant acute graft versus host disease</keyword>
  <keyword>steroid-refractory acute graft versus host disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

